PARIS (Agefi-Dow Jones)–Valneva announced Monday that regulator Health Canada has approved IXCHIQ, the biotechnology company’s single-shot vaccine, to prevent chikungunya virus disease in older adults ages 18 and older.
Valneva, which has already begun marketing the IXCHIQ vaccine in the United States this year, plans to sell the first doses in Canada in the fourth quarter of 2024. The European Medicines Agency also recently recommended the approval of this vaccine in Europe, and an official decision is expected in the third quarter of the current year.
IXCHIQ is the world’s only licensed chikungunya vaccine that addresses an unmet medical need. Each year, more than 65 million North Americans, including about 7 million Canadians, travel to countries where chikungunya is endemic.
-Dimitri Delmond, Agefi-Dow Jones; +33 (0)1 41 27 47 31; ddelmond@agefi.fr Editor: FXS
Agefi-Dow Jones The financial intelligence service
Dow Jones Newswires
June 24, 2024 01:15 ET (05:15 GMT)
Which stocks to buy?
Making the best investments requires a detailed knowledge of the markets, their mechanisms and the economy, and it is about getting to the heart of the strategy of each listed company. The Investir editorial team does this for you, advising its subscribers on more than 800 stocks. Benefit from their buy, speculative buy, spread or sell recommendations by subscribing to Investir.
I discover the offers
Award-winning entrepreneur. Baconaholic. Food advocate. Wannabe beer maven. Twitter ninja.
